⚠️ Fraud Alert: Beware of Forged Documents — It has come to our notice that unauthorized individuals are using fake Plexus letterheads and forged signatures to solicit money. We have reported the matter to the authorities and are pursuing legal action. If you receive any suspicious letter, message, or call claiming to be from Plexus, please do not engage. To verify, contact us at 📞 9355533404 | 📧 info@plexusnc.com — Please stay alert and help us spread the word.
⚠️ Fraud Alert: Beware of Forged Documents — It has come to our notice that unauthorized individuals are using fake Plexus letterheads and forged signatures to solicit money. We have reported the matter to the authorities and are pursuing legal action. If you receive any suspicious letter, message, or call claiming to be from Plexus, please do not engage. To verify, contact us at 📞 9355533404 | 📧 info@plexusnc.com — Please stay alert and help us spread the word.

Parkinson’s Disease Tests and Diagnosis

Is there a test for Parkinson’s disease? There is currently no single blood test or scan that can confirm Parkinson’s disease on its own. A neurologist reviews symptoms and medical history and performs a detailed neurological examination. Tests for Parkinson’s disease, including DaTscan, MRI and blood tests, can support diagnosis or help rule out other conditions.

Parkinson’s disease is a progressive neurological condition, and its causes are not fully understood. See our guide to Parkinson’s disease causes and risk factors for more information. Genetic, environmental and biological factors may contribute to its development. Current medical care focuses on managing symptoms, supporting daily activities and helping people maintain their independence.

Is There a Single Test for Parkinson’s Disease?

There is no single test for Parkinson’s diagnosis that definitively confirms every case. When people talk about a test for Parkinson’s, they usually mean the overall clinical assessment performed by a neurologist or movement disorder specialist.

The Movement Disorder Society’s 2015 clinical diagnostic criteria were developed to make Parkinson’s disease diagnosis more consistent. The criteria identify parkinsonism through bradykinesia combined with resting tremor or rigidity, then use supportive features, warning signs and exclusion criteria to assess diagnostic confidence. They distinguish clinically established from clinically probable Parkinson’s disease. The criteria help structure the assessment, but diagnosis still depends on clinical judgement rather than a single definitive test.

How Is Parkinson’s Disease Diagnosed?

Parkinson’s diagnosis involves reviewing symptoms, medical history, medication history and changes in movement over time. Diagnosis relies mainly on clinical assessment and may require follow-up visits when symptoms are unclear.

A 2020 JAMA review examined the diagnosis and management of Parkinson’s disease. The review recognised the importance of medical history and neurological examination in establishing the diagnosis and outlined the role of imaging in selected uncertain cases. The review also addressed motor and non-motor symptoms, with particular attention to symptoms that may be present before changes in movement. It concluded that Parkinson’s disease is still diagnosed clinically; no single test confirms every case.

A 2021 review published in The Lancet examined the biology, clinical features, progression and management of Parkinson’s disease. It detailed differences in symptoms and progression between individuals, reflecting the complexity of the disorder. These differences reinforce the importance of assessing each person’s symptoms and medical history rather than relying on a single test or explanation.

The Neurological Examination

Tests to determine Parkinson’s disease usually begin with an examination of movement, muscle tone, coordination and balance. A clinician may ask the person to perform finger tapping, toe tapping and hand opening and closing, then assess gait, walking speed and arm swing.

The examination may identify cogwheel rigidity, resting tremor or postural instability. A pull test may help assess balance and the ability to recover from a backward movement.

A 2008 MDS-UPDRS study published in Movement Disorders evaluated a revised scale for assessing Parkinson’s disease. It covered non-motor symptoms, daily activities, motor examination and motor complications, with evidence supporting its reliability and validity. The scale helps clinicians measure symptom severity and track changes over time. However, it was designed to assess the condition, not to identify its cause or independently confirm a diagnosis.

A 2016 systematic review and meta-analysis published in Neurology investigated how accurately clinicians could diagnose Parkinson’s disease when compared to neuropathological confirmation. Diagnostic accuracy was limited, especially at the beginning of the disease and tended to improve with longer follow-up. This highlights why early symptoms can be difficult to distinguish from those of other disorders and why reassessment may be needed.

Imaging Tests: DaTscan, MRI and Other Scans

Parkinson’s disease diagnostic tests may include imaging when the diagnosis is uncertain or another neurological condition needs to be investigated.

  • DaTscan: A type of single-photon emission computed tomography (SPECT) scan that shows how much dopamine transporter activity there is in the part of the brain affected by Parkinson’s.
  • MRI: Helps investigate structural causes, including stroke, brain tumour or normal pressure hydrocephalus, but does not confirm Parkinson’s disease.
  • CT scan: May help identify structural abnormalities in selected cases.
  • PET scan and transcranial ultrasound: May have specialised roles depending on the clinical question and local availability.

A 2013 DaT-SPECT review published in the Journal of Neurology, Neurosurgery, & Psychiatry assessed whether dopamine transporter imaging could help differentiate parkinsonian syndromes. It found that the scan can help distinguish essential tremor and some non-degenerative causes of parkinsonism from conditions involving reduced dopamine transporter availability. However, it cannot reliably separate Parkinson’s disease from every other degenerative parkinsonian condition. Its role is to help answer specific diagnostic questions, not to provide a definitive diagnosis in every case.

The UK’s NICE guideline on Parkinson’s disease in adults recommends clinical diagnosis by an appropriately qualified specialist and advises against using structural MRI to diagnose Parkinson’s disease. It recommends considering dopamine transporter SPECT when essential tremor cannot be distinguished clinically from parkinsonism. These recommendations distinguish tests that support an assessment from those that cannot definitively confirm the disease.

Blood Tests and Other Laboratory Tests

Routine blood tests cannot confirm Parkinson’s disease. Depending on symptoms and medical history, clinicians may check thyroid function, vitamin B12 and liver function, or investigate other possible causes of movement changes. Copper studies may be considered in younger patients when a condition such as Wilson’s disease is suspected.

These tests help rule out conditions that can mimic Parkinson’s disease. Normal results do not establish the diagnosis.

Alpha-Synuclein Biomarker Tests

Some tests for Parkinson’s disease investigate alpha-synuclein, a protein associated with Parkinson’s disease and other synucleinopathies. These Parkinson’s disease diagnostic tests remain an area of biomarker research.

A 2023 study published in The Lancet Neurology evaluated a cerebrospinal fluid (CSF) alpha-synuclein seed amplification assay in Parkinson’s Progression Markers Initiative participants. The assay identifies abnormal alpha-synuclein activity by assessing its ability to induce further protein aggregation. The study found 87.7% sensitivity for Parkinson’s disease and 96.3% specificity in healthy controls. The positivity rate differed among clinical presentations and genetic groups, suggesting that the underlying biology identified by the assay is not the same in all patients. The findings support further biomarker research, but the assay does not replace clinical assessment.

A 2024 JAMA study investigated detecting phosphorylated alpha-synuclein in skin biopsies from people with synucleinopathies. The protein was detected in 92.7% of participants with Parkinson’s disease, but it was also found in people with multiple system atrophy, dementia with Lewy bodies and other related conditions. This means that detecting the protein may help identify a group of neurological disorders but cannot, by itself, establish that a person has Parkinson’s disease. The findings are promising, but the test cannot distinguish Parkinson’s disease from every related condition on its own.

CSF analysis requires a lumbar puncture, and skin biopsy requires the removal of a tiny piece of skin. These tests are not widely available, and none is used on its own to confirm Parkinson’s disease.

Genetic Testing for Parkinson’s

A genetic test for Parkinson’s may be considered when symptoms begin at a younger age, or there is a family history. Testing may examine genes such as LRRK2, GBA1 and PRKN. Genetic counselling can help explain the implications of results for the person and their family.

Response to Parkinson’s Medicine

A clinician may also consider whether symptoms improve with dopaminergic medicine, such as levodopa. The response to levodopa can help in the diagnosis of Parkinson’s disease, but it does not prove the disease, as other conditions may also respond.

It is important to distinguish a supervised medication assessment from a definitive test. The NICE guideline advises against using acute levodopa or apomorphine challenge tests to differentiate parkinsonian syndromes. Medication trials should be guided by a healthcare professional.

Conditions That Can Look Like Parkinson’s

Several conditions can resemble Parkinson’s disease. Essential tremor often causes shaking during movement or while holding a posture. Drug-induced parkinsonism may occur after taking certain medicines, while vascular parkinsonism can be associated with cerebrovascular disease.

Other conditions include multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and dementia with Lewy bodies. Normal pressure hydrocephalus may cause walking difficulties and cognitive changes. Dementia with Lewy bodies is a related condition, but it differs from Parkinson’s disease dementia in the timing and pattern of symptoms. Read our guide to how dementia, Alzheimer’s and Parkinson’s differ for more information about related forms of dementia.

Recognising these conditions is important because their management and progression can differ. Follow-up and reassessment can help address possible Parkinson’s misdiagnosis.

Early Diagnosis of Parkinson’s Disease

Early diagnosis of Parkinson’s disease can be difficult because some symptoms appear before characteristic movement changes. Possible prodromal symptoms include loss of smell, constipation, low mood, anxiety and REM sleep behaviour disorder, in which a person physically acts out dreams.

Learn more about these changes in our guide to early signs of Parkinson’s disease.

The 2015 MDS research criteria for prodromal Parkinson’s disease, published in Movement Disorders and updated in 2019, combined risk factors, early symptoms, and biomarkers to estimate the likelihood of developing Parkinson’s disease before typical motor symptoms appear. The criteria were intended for research, not as a standalone clinical diagnosis. They help researchers study whether Parkinson’s disease may be identified earlier, but risk factors and early symptoms cannot establish with certainty who will develop it. These signs do not alone confirm a diagnosis of Parkinson’s disease. Digital monitoring and wearable devices are also under investigation for detecting subtle changes in movement, but they cannot substitute for clinical evaluation.

Preparing for Your Neurology Appointment

Before your appointment, keep a symptom diary recording when symptoms began, how they change and how they affect daily activities. Bring a medication list, relevant medical records and details of family history. A video showing tremor or walking difficulties may help if symptoms fluctuate.

Ask which conditions are being considered, whether further tests are needed and when the diagnosis should be reviewed. Bringing a family member or caregiver can help with recalling symptoms and discussing next steps. 

How Plexus Supports People After a Parkinson’s Diagnosis

If you have noticed symptoms but have not been diagnosed, start with a neurologist, who can arrange any tests that are needed. Care after a diagnosis focuses on managing symptoms, supporting independence and maintaining quality of life.

At Plexus, with centres in Bangalore and Hyderabad, support begins with a doctor-led assessment of how the condition is affecting the person: tremors, movement, balance, speech, thinking and mood. A plan may then bring together physiotherapy, occupational therapy, specialised speech and movement therapy, cognitive rehabilitation, mental health therapy, and Cell Therapy for patients found eligible after assessment. Caregivers are taught the home exercises and handling techniques as part of the programme. The plan is reviewed regularly and adjusted as needs change. Individual outcomes vary.

Explore our rehabilitation and physiotherapy services to learn more about the support available.

If you would like to talk through what support might help after a diagnosis, contact Plexus to enquire.

FAQs

Is there a blood test for Parkinson’s disease?

No. Routine blood tests cannot confirm Parkinson’s disease, but they can help investigate other causes of similar symptoms.

What is the most accurate test for Parkinson’s disease?

There is no single definitive test. Clinical examination by a neurologist is central to diagnosis, with additional investigations used when appropriate.

Can an MRI scan detect Parkinson’s disease?

No. A standard MRI cannot confirm Parkinson’s disease, but it may help identify other causes of movement symptoms.

What is a DaTscan and when is it used?

A DaTscan is a type of SPECT scan that shows how much dopamine transporter activity there is in the part of the brain affected by Parkinson’s. It may help distinguish essential tremor from certain parkinsonian syndromes when the diagnosis is unclear.

Which doctor diagnoses Parkinson’s disease?

A neurologist, ideally a movement disorder specialist, can assess symptoms and investigate alternative diagnoses.

How long does it take to get a Parkinson’s diagnosis?

The time varies. Some cases can be identified at an initial assessment, while uncertain cases may require further investigations and follow-up visits.

Can Parkinson’s disease be diagnosed early?

Sometimes. Early symptoms can be hard to tell apart from other conditions, so diagnosis may take follow-up visits. Changes such as loss of smell or acting out dreams can come before movement symptoms, but they cannot confirm Parkinson’s on their own.

Can Parkinson’s disease be misdiagnosed?

Yes. Essential tremor, medication effects and atypical parkinsonian disorders can resemble Parkinson’s disease. Follow-up assessments can help clarify an uncertain diagnosis.

Sources

Armstrong, M. J., & Okun, M. S. (2020). Diagnosis and treatment of Parkinson disease: A review. JAMA, 323(6), 548–560. https://doi.org/10.1001/jama.2019.22360

Bajaj, N., Hauser, R. A., & Grachev, I. D. (2013). Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (¹²³I) ioflupane in diagnosis of parkinsonian syndromes. Journal of Neurology, Neurosurgery & Psychiatry, 84(11), 1288–1295. https://doi.org/10.1136/jnnp-2012-304436

Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G., Joseph, L., Lang, A. E., Liepelt-Scarfone, I., Litvan, I., Marek, K., Obeso, J., Oertel, W., Olanow, C. W., Poewe, W., Stern, M., & Deuschl, G. (2015). MDS research criteria for prodromal Parkinson’s disease. Movement Disorders, 30(12), 1600–1611. https://doi.org/10.1002/mds.26431

Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X

Gibbons, C. H., Levine, T., Adler, C., Bellaire, B., Wang, N., Stohl, J., Agarwal, P., Aldridge, G. M., Barboi, A., Evidente, V. G. H., Galasko, D., Geschwind, M. D., Gonzalez-Duarte, A., Gil, R., Gudesblatt, M., Isaacson, S. H., Kaufmann, H., Khemani, P., Kumar, R., … Freeman, R. (2024). Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA, 331(15), 1298–1306. https://doi.org/10.1001/jama.2024.0792

Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez-Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., Dubois, B., Holloway, R., Jankovic, J., Kulisevsky, J., Lang, A. E., Lees, A., Leurgans, S., LeWitt, P. A., Nyenhuis, D., … LaPelle, N. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 23(15), 2129–2170. https://doi.org/10.1002/mds.22340

Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C., Postuma, R. B., & MDS Task Force on the Definition of Parkinson’s Disease. (2019). Update of the MDS research criteria for prodromal Parkinson’s disease. Movement Disorders, 34(10), 1464–1470. https://doi.org/10.1002/mds.27802

National Institute for Health and Care Excellence. (2017). Parkinson’s disease in adults: Diagnosis and management (NICE Guideline NG71). https://www.nice.org.uk/guidance/ng71

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., Halliday, G., Goetz, C. G., Gasser, T., Dubois, B., Chan, P., Bloem, B. R., Adler, C. H., & Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. https://doi.org/10.1002/mds.26424

Rizzo, G., Copetti, M., Arcuti, S., Martino, D., Fontana, A., & Logroscino, G. (2016). Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology, 86(6), 566–576. https://doi.org/10.1212/WNL.0000000000002350

Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., Galasko, D., Kieburtz, K., Merchant, K., Mollenhauer, B., Poston, K. L., Seibyl, J., Simuni, T., Tanner, C. M., Weintraub, D., … Soto, C. (2023). Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification: A cross-sectional study. The Lancet Neurology, 22(5), 407–417. https://doi.org/10.1016/S1474-4422(23)00109-6

Educational disclaimer: For educational purposes only, not medical advice. Treatment decisions require professional consultation.

Medically Reviewed By

Dr. Na’eem Sadiq

Medical Director of Plexus

Medically reviewed: October 30, 2026

Dr. Na’eem Sadiq is a neurologist and neuropsychiatrist with over 35 years of clinical experience in treating complex neurological disorders. He founded Plexus in 2011 with a mission to enhance the quality of life for people living with neurological conditions. His areas of expertise include Neurology, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, Migraine, Demyelinating Polyneuropathy and Cell Therapy.

WhatsApp chat
Book a Free Consultation
Translate »

Need help deciding the next step?

Share your details and our care team will call you back.

Now available: 0 down payment treatment financing with Bajaj Finance.

    By clicking 'Submit', you agree to Terms of Use

    Before you go

    Many families start with a free medical review. No commitment.

    Now available: 0 down payment treatment financing with Bajaj Finance.

      By clicking 'Submit', you agree to Terms of Use